Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
Melbourne (Australia) and Porto Alegre (Brazil) – 1 December 2021. The Brazilian Health Regulatory Agency has granted an exceptional authorisation...
First Telix and Duchembio Joint Symposium – Emergence of PSMA-PET Imaging in South Korea
22 November 2021 – Clinical Spotlight | Telix and Duchembio announce a joint symposium on 68Ga-PSMA-PET imaging in Korea
NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed
Melbourne (Australia) – 15 November 2021. The first Australian patient has been dosed in the international NOBLE Registry, a study aimed at improving access to state-of-the-art prostate...
Australian TGA Approves Illuccix® for Prostate Cancer Imaging
Melbourne (Australia) – 02 November 2021. Australian Therapeutic Goods Administration has approved Illuccix® for the diagnostic imaging of men with prostate...